Rapport Services

Rapport Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for neurological disorders. The company utilizes its proprietary RAP (Receptor-Associated Protein) technology platform to identify and target proteins that determine the precise neurocircuitry of specific receptors. By targeting these receptor-associated proteins rather than the receptors themselves, Rapport aims to create therapies with improved specificity and reduced side effects. Its lead candidate, RAP-219, is a selective AMPA receptor modulator currently in Phase 2 clinical trials for the treatment of focal epilepsy. The company's pipeline also includes programs for neuropathic pain, bipolar disorder, and hearing loss.